Sign in
Not yet recruitingPhase 2

HLX22 Combination Therapy in HER2-Positive Limited Metastatic Gastric Cancer

Key facts

Who runs it
Shanghai Zhongshan Hospital
Trial code
Status
Not yet recruiting
Phase
Phase 2
People taking part
30 people, planned
Starts
1 Dec 2026
Expected to end
31 Dec 2029
Type of study
Interventional, 2 groups
Treatments tested
  • HLX22
  • Trastuzumab
  • XELOX Chemotherapy
  • HLX10
Record updated
17 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 35 criteriaShow less

Who can take part

  • Subjects must meet all of the following inclusion criteria:
  • Voluntarily participate in this clinical study; fully understand and be informed of the study; sign the informed consent form (ICF); and be willing and able to comply with and complete all study procedures
  • At the time of signing the informed consent form, the subject is a male or female aged ≥18 years
  • Histologically or cytologically confirmed gastric or gastroesophageal junction adenocarcinoma that has not been previously treated
  • Presence of measurable lesions according to RECIST version 1.1; target lesions must not consist solely of bone metastases
  • HER2-positive tumor, defined as IHC 3+, or IHC 2+ with ISH-positive or FISH-positive
  • Limited metastatic disease assessed by a multidisciplinary team (MDT) and deemed unresectable; Limited distant metastasis is defined as meeting only a or a single b ± a, as follows:; Abdominal non-regional lymph node metastases, including metastases to the superior mesenteric artery lymph nodes, middle colic artery lymph nodes, para-aortic or retroperitoneal lymph nodes; b1. Limited peritoneal metastasis (P0CY1 or P1a or P1b):P0CY1 is defined as the presence of malignant tumor cells detected by cytological examination of ascites or peritoneal lavage fluid during laparoscopic exploration, without macroscopic visible peritoneal metastatic lesions;P1a is defined as peritoneal metastases limited to areas adjacent to the stomach, greater omentum, lesser omentum, anterior leaf of the transverse mesocolon, pancreatic capsule, and spleen;P1b is defined as peritoneal metastases in the upper abdomen, specifically involving the parietal peritoneum above the umbilicus and the visceral peritoneum above the transverse colon; b2. Liver metastases, with no more than 5 metastatic lesions; b3. Lung metastases, unilateral involvement only, with no more than 5 metastatic lesions; b4. Unilateral or bilateral ovarian metastases; b5. Unilateral or bilateral adrenal gland metastases; b6. Extra-abdominal lymph node metastases confined to a single region, such as cervical lymph nodes, supraclavicular lymph nodes, or mediastinal lymph nodes; b7. Bone metastases confined to a single radiation field; b8. Other limited distant metastases as determined by evaluation of the study team
  • No prior antitumor treatment
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1
  • Expected survival time ≥ 6 months
  • Hepatitis B surface antigen (HBsAg) negative and hepatitis B core antibody (HBcAb) negative; if HBsAg positive or HBcAb positive, hepatitis B virus DNA (HBV-DNA) must be < 2500 copies/mL or 500 IU/mL, or within the normal range of the study institution (if the study center has a defined normal range, the HBV-DNA result must fall within that range)
  • Hepatitis C virus (HCV) antibody negative; if HCV antibody positive, HCV-RNA must be negative prior to enrollment. Subjects with concurrent hepatitis B and hepatitis C infection (HBsAg or HBcAb positive and HCV antibody positive) must be excluded
  • Human immunodeficiency virus (HIV) antibody negative
  • Adequate organ function, meeting the following criteria (within 14 days prior to randomization, without receiving blood transfusion, albumin, recombinant human thrombopoietin, or colony-stimulating factor [CSF] treatment):; Hematologic function Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L Platelet count (PLT) ≥ 100 × 10⁹/L Hemoglobin (Hb) ≥ 90 g/L; Hepatic function Total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN) Alanine aminotransferase (ALT) ≤ 2.5 × ULN; ≤ 5.0 × ULN for patients with liver metastases Aspartate aminotransferase (AST) ≤ 2.5 × ULN; ≤ 5.0 × ULN for patients with liver metastases Alkaline phosphatase (ALP) ≤ 2.5 × ULN; ≤ 5.0 × ULN for patients with liver metastases and/or bone metastases Albumin ≥ 25 g/L; Renal function Creatinine clearance (CrCl) ≥ 50 mL/min (calculated according to the Cockcroft-Gault formula); Coagulation function Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN Prothrombin time (PT) ≤ 1.5 × ULN International normalized ratio (INR) ≤ 1.5 × ULN
  • Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days prior to randomization. Female subjects of childbearing potential and male subjects with partners of childbearing potential must use at least one highly effective contraceptive method as defined by the Clinical Trial Facilitation Group (CTFG) during the study treatment period and for at least 9 months after the last study treatment (such as intrauterine devices, oral contraceptives, condoms, female or male sterilization, etc.)

Who cannot take part

  • Prior treatment for locally advanced unresectable or metastatic gastric cancer or gastroesophageal junction adenocarcinoma. However, subjects who have received perioperative treatment (neoadjuvant or adjuvant therapy) may be enrolled if there was no disease progression for at least 6 months from completion of treatment to randomization
  • Prior use of doxorubicin with a cumulative dose > 360 mg/m² (or equivalent drugs); note: equivalent drugs include epirubicin > 720 mg/m², mitoxantrone > 120 mg/m², idarubicin > 90 mg/m², or cumulative exposure exceeding the equivalent of 360 mg/m² doxorubicin using liposomal doxorubicin or other anthracycline antibiotics. If more than one anthracycline antibiotic was used, the cumulative dose must not exceed the equivalent of 360 mg/m² doxorubicin
  • Prior receipt of any HER2-targeted therapy
  • Residual toxicity from previous treatments. Alopecia is allowed
  • Receipt of live vaccines within 28 days prior to randomization; seasonal influenza vaccines or inactivated COVID-19 vaccines are excluded from this restriction
  • Major surgery within 28 days prior to randomization
  • Curative radiotherapy within 28 days prior to randomization
  • Participation in another investigational drug study or use of investigational devices within 28 days prior to randomization
  • Known severe allergy to any monoclonal antibody or excipients of the investigational drugs
  • Lactating subjects. Subjects who discontinued breastfeeding prior to signing the informed consent form and will not breastfeed during the study may be enrolled. Breastfeeding must not be resumed during the study treatment period, and breastfeeding may be resumed 9 months after completion of study treatment
  • Known dihydropyrimidine dehydrogenase (DPD) deficiency or current use of antiviral drugs such as sorivudine or chemically related analogs, such as brivudine
  • Subjects with other malignancies within the past 2 years. Subjects with cured localized tumors, such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, prostate carcinoma in situ, cervical carcinoma in situ, breast carcinoma in situ, and thyroid cancer may be enrolled
  • Active gastrointestinal bleeding (grade ≥ 2 according to the National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version 6.0)
  • Presence of central nervous system (CNS) metastases and/or leptomeningeal disease
  • Active infection requiring systemic treatment or active pulmonary tuberculosis; history of interstitial lung disease or complicated interstitial lung disease
  • Known history of psychotropic substance abuse or drug dependence
  • Cerebrovascular accident, myocardial infarction, unstable angina, or uncontrolled arrhythmia (including QTc interval ≥ 470 ms, calculated using Fridericia's formula) occurring within 6 months prior to randomization
  • New York Heart Association (NYHA) class III or IV heart failure, or left ventricular ejection fraction (LVEF) < 55% as assessed by color Doppler echocardiography (ECHO)
  • Any previous or current clinical condition, laboratory abnormality, or other situation that, in the investigator's judgment, may interfere with the results of this study or for which participation in this study would not be in the best interest of the subject
  • Subjects meeting any of the following exclusion criteria will not be eligible for this study:

About the trial

What the trial wants to find out

This is a prospective, open-label, exploratory study evaluating the efficacy and safety of HLX22 in combination with first-line systemic therapy in patients with HER2-positive, limited metastatic, unresectable gastric or gastroesophageal junction adenocarcinoma. Patients will receive HLX22 combined with trastuzumab and XELOX chemotherapy, with or without the PD-1 inhibitor HLX10 according to PD-L1 and mismatch repair status. The primary endpoint is objective response rate assessed by RECIST v1.1.

The 2 groups in the trial

  • CPS≥5 and/or dMMRTreatment being tested

    Participants with PD-L1 combined positive score (CPS) ≥5 and/or deficient mismatch repair (dMMR) tumors will receive HLX22 in combination with trastuzumab, XELOX chemotherapy, and the PD-1 inhibitor HLX10 as first-line treatment.

    Treatment: HLX22, Trastuzumab, XELOX Chemotherapy, and HLX10

  • CPS <5 and pMMRTreatment being tested

    Participants with PD-L1 combined positive score (CPS) \<5 and proficient mismatch repair (pMMR) tumors will receive HLX22 in combination with trastuzumab and XELOX chemotherapy as first-line treatment.

    Treatment: HLX22, Trastuzumab, and XELOX Chemotherapy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Exploratory Clinical Study to Evaluate the Efficacy and Safety of HLX22 in Combination With First-Line Therapy for HER2-Positive, Limited Metastatic, Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma
Record updated
17 November 2026